Onxeo is a biotechnology company that designs and develops innovative medicines for the treatment of cancer and its associated pathologies, more specifically for severe or rare diseases with orphan status.
Onxeo is focused on bringing early-stage first-in-class or disruptive compounds (proprietary, acquired or in-licensed) from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
Onxeo was founded in 2014, through a merger of BioAlliance Pharma, a French biotechnology company, and TopoTarget, a Danish biotechnology company. Onxeo is based in Paris, Ile-de-France, France with an additional office in Denmark.
Onxeo’s R&D pipeline includes belinostat, an HDAC inhibitor (epigenetics) currently being developed in oral form to be used in combination with other anti-cancer agents for liquid or solid tumors.
Onxeo is also developing AsiDNA™, a first-in-class DNA break repair inhibitor based on a unique decoy mechanism. AsiDNA™ has already successfully completed a Phase I trial in metastatic melanoma via local administration, and is currently being developed for systemic (IV) administration in solid tumors.
Onxeo is a venture backed company that went public on Dec 16, 2005. The company has acquired DNA Therapeutics on Feb 29, 2016.